GLP-1 Agonists
- Name
- GLP-1 Agonists
- Accession Number
- DBCAT002693 (DBCAT003437, DBCAT003869, DBCAT004144)
- Description
Glucagon-like peptide-1 receptor agonists also known as GLP-1 receptor agonists or incretin mimetics are agonists of the GLP-1 receptor. This class of drugs is used for the treatment of type 2 diabetes.
- Drugs
Drug Drug Description Exenatide A GLP-1 agonist used in the management of type 2 diabetes mellitus. Liraglutide A GLP-1 analog used in the management of type 2 diabetes mellitus, prevention of cardiovascular complications associated with diabetes, and obesity. Albiglutide A GLP-1 agonist used to manage type 2 diabetes mellitus. Dulaglutide A GLP-1 agonist used to manage type 2 diabetes mellitus. Taspoglutide Taspoglutide is a pharmaceutical drug, a glucagon-like peptide-1 agonist (GLP-1 agonist), under investigation for treatment of type 2 diabetes being codeveloped by Ipsen and Roche. In September 2010 Roche halted... Lixisenatide A GLP-1 receptor agonist used for the management of type 2 diabetes mellitus. Semaglutide A glucagon-like peptide 1 receptor agonist used to improve glycemic control in type 2 diabetes mellitus, treat obesity, and reduce the risk of major adverse cardiovascular events in selected adults. Tirzepatide A dual GIP and GLP-1 receptor agonist used for the treatment of type II diabetes in adults as an adjunct to diet and exercise. - Drugs & Drug Targets